Johnson & Johnson Accelerates Divestiture of DePuy Synthes, Investors Optimistic About Streamlined Strategy

Johnson & Johnson announced the CHMP recommended approval for TECVAYLI (teclistamab) in adults with relapsed or refractory multiple myeloma after at least one prior therapy. The recommendation follows phase 3 results showing improved progression-free and overall survival. The company highlighted the critical need for effective immunotherapies in earlier treatment lines.

Johnson & Johnson (JNJ) is considering selling its orthopedics unit, DePuy Synthes, for $20 billion to Apollo Global Management. The move aligns with J&J's strategy to streamline operations and focus on higher-growth, higher-margin businesses. According to the company, this will accelerate its shift toward more profitable markets. The sale could provide J&J with cash for stock buybacks, debt reduction, or reinvestment.

Johnson & Johnson (JNJ) received EU approval for ICOTYDE, a once-daily oral treatment for moderate-to-severe plaque psoriasis. The approval was based on positive Phase 3 trial data, with about 70% of patients achieving clear or almost clear skin. ICOTYDE is the first targeted oral peptide blocking the IL-23 receptor. JNJ's stock is currently trading at $272.39, up 0.89%.

Johnson & Johnson (JNJ) reported positive phase 3 trial results for its bipolar I disorder drug Caplyta, showing significant efficacy. The company offers a 1.93% dividend yield with a 50% payout ratio and a 4.9% 3-year dividend growth rate. JNJ's stock is trading 40.1% above its intrinsic GF Value™ of $193.54. The company has a GF Score™ of 80, reflecting strong financial health and profitability, but weaker valuation and momentum.

Johnson & Johnson's (JNJ) lumateperone (Caplyta) showed significant reduction in manic symptoms in a Phase III trial for bipolar I disorder, according to topline results. The drug is already approved for bipolar depression and J&J plans to discuss FDA filing for mania. Study 451 showed a 4.8-point greater reduction in YMRS score vs. placebo. J&J acquired Intra-Cellular Therapies for $14.6B in 2025, with Caplyta's expansion central to the deal.

Johnson & Johnson (JNJ) reported positive Phase 3 trial results for CAPLYTA in treating acute manic episodes in adults with bipolar I disorder. The drug showed significant improvement in mania symptoms compared to placebo, with a 4.8-point greater reduction in YMRS scores. A second Phase 3 study has completed enrollment, with data analysis ongoing. JNJ stated CAPLYTA's safety profile was consistent with previous findings.